- Home
- AARD vs PROK Comparison
AARD vs PROK Comparison
Compare AARD & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | PROK |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 331.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AARD | PROK |
|---|---|---|
| Price | $5.80 | $2.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $19.63 | $7.40 |
| AVG Volume (30 Days) | 325.0K | ★ 573.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,000.00 |
| Revenue This Year | N/A | $1,010.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $0.46 |
| 52 Week High | $17.94 | $7.13 |
Technical Indicators
Market Signals| Indicator | AARD | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 24.24 | 62.03 |
| Support Level | $4.74 | $2.09 |
| Resistance Level | $15.88 | $2.58 |
| Average True Range (ATR) | 0.54 | 0.15 |
| MACD | -0.55 | 0.03 |
| Stochastic Oscillator | 12.99 | 78.70 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.